BVI Medical - Global Leader in Ophthalmic Surgical Devices

📢 Key Milestones (2025–2026):
   In March 2025, BVI Medical completed a $1 billion strategic capital raise in partnership with TPG. In April 2025, the FDA cleared the Leos™ Laser Endoscopy Ophthalmic System for glaucoma surgery. In October 2025, the FDA approved the FINEVISION HP trifocal IOL for the U.S. market. In September 2025, BVI unveiled Virtuoso®, a dual-function phaco-vitrectomy platform. In January 2026, Jim Hollingshead was appointed President and CEO. In April 2026, Virtuoso® received EU MDR CE Mark certification, with the first patient treated in December 2025 at LMU Klinikum in Munich.

Company Profile (Updated April 2026)

BVI Medical (formerly Beaver-Visitec International) is a diversified global ophthalmic device company headquartered at 303 Wyman Street, Suite 350, Hobbs Brook Office Park, Waltham, Massachusetts, USA. The company's heritage traces back to 1932, while its current corporate structure was formed in 2010 when RoundTAble Healthcare Partners acquired and integrated three ophthalmic product businesses from Becton Dickinson, Medtronic, and Aspen Surgical. In 2016, TPG Capital acquired BVI from RoundTable, and TPG remains the controlling private equity owner today.

BVI Medical partners with ophthalmic surgeons to improve the vision of millions of patients across the globe. The organization supports surgical teams in more than 90 countries worldwide, either directly or through a network of trusted distributors. The company operates manufacturing and sales facilities across North America, Europe, Asia, and Latin America.

Development History:

- 1932: Origins trace back to the founding of predecessor brands that would later become part of BVI

- 2010: RoundTable Healthcare Partners formed BVI by acquiring and integrating ophthalmic businesses from Becton Dickinson, Medtronic, and Aspen Surgical

- 2016: TPG Capital acquired BVI from RoundTable Healthcare Partners

- 2019: Launched ISOPURE premium monofocal IOL family

- 2020: Launched first intraocular lens in the U.S. — the monofocal IPure

- 2021: Shervin Korangy appointed President and CEO; company embarked on strategic transformation

- 2023: Opened new IOL manufacturing facility in Belgium; acquired Medical Mix in Spain and Portugal; expanded IOL market through acquisitions of PhysIOL Group and Benz Research & Development

- 2024: Launched SERENITY and SERENITY Toric premium monofocal IOLs with patented ISOFOCAL technology

- 2025.03: Completed $1 billion strategic capital raise with TPG, fully refinancing debt and adding new equity

- 2025.04: FDA 510(k) clearance for Leos™ Laser Endoscopy Ophthalmic System for glaucoma treatment

- 2025.07: First clinical use of Leos™ performed by Dr. Nathan Radcliffe in New York

- 2025.08: Launched ISPAN™ ophthalmic gases (SF₆ and C₃F₈) for the U.S. retinal tamponade market

- 2025.09: European unveiling of Virtuoso® dual-function phaco-vitrectomy system at ESCRS and Euretina congresses

- 2025.10: FDA approval of FINEVISION HP trifocal IOL; first U.S. implantations performed by five leADINg surgeons

- 2025: Established BVI Poland in Krakow as a Centre of Excellence for finance, customer operations, regulatory affairs, quality assurance, HR, and talent acquisition

- 2026.01: Jim Hollingshead appointed President and CEO; Shervin Korangy transitioned to advisory role and senior advisor to TPG Capital

- 2026.04: Virtuoso® received EU MDR CE Mark; first patient treated in December 2025 at LMU Klinikum, Munich

Core Mission: To deliver high-quality solutions and innovation for advancing eye surgery and improving patients' vision, partnering with ophthalmic surgeons to improve the vision of millions of patients across the globe.

Core Product Portfolio

Intraocular Lenses (IOLs)

- FINEVISION HP: Hydrophobic trifocal IOL with proprietary POD platform and CoPODize™ technology; FDA approved October 2025; world's first trifocal IOL with 15+ years of global clinical use

- SERENITY / SERENITY Toric: Premium monofocal IOLs with patented ISOFOCAL optic technology providing distance and intermediate vision up to 66 cm; second generation of the ISOPURE family

- ISOPURE: Premium monofocal IOL family launched in 2019

- IPure: Monofocal IOL; BVI's first IOL launched in the U.S. in 2020

- PODEYE: Hydrophobic monofocal IOL with proprietary double C-loop POD platform and GFY® 100% glistening-free material

- PhysIOL: Premium IOL brand with toric calculator featuring Abulafia-Koch regression formula

Cataract & Vitreoretinal Surgical Systems

- Virtuoso®: Novel dual-function phaco-vitrectomy platform for both cataract and vitreoretinal procedures; EU MDR CE Mark ACHieved April 2026; first patient treated December 2025 in Munich

- Endo Optiks E2 / E4: Ophthalmic laser endoscopy systems combining high-resolution video imaging with 810nm diode laser treatment for glaucoma and retinal disorders

Glaucoma Treatment

- Leos™: Laser Endoscopy Ophthalmic System; first and only FDA-cleared digital endoscopy and laser system for minimally invasive ab interno intraocular pressure reduction; commercial launch planned for late 2025

Single-Use Instruments & Consumables

- Beaver®: Knives, blades, and mini-blades manufactured with proprietary grindless technology

- Visitec®: Cannulae, cystotomes, and irrigation instruments

- Malosa®: Single-use instruments

- Merocel® / Weck-Cel®: Ophthalmic fluid management and sponge products

- Wet-Field® Eraser®: Bipolar electrosurgery instruments for hemostasis in vitreoretinal and glaucoma procedures

- Accu-Temp®: Low-temperature cautery devices

- Vitreq®: Vitreoretinal surgical products including ISPAN™ ophthalmic gases (SF₆, C₃F₈)

- Parasol® / Micro Flow™: Punctal occluders for dry eye and lacrimal disorders

- Readypak™: Custom-configured ophthalmic surgical kits

Regulatory & Awards

- FDA 510(k) Clearances: Leos™ glaucoma system (April 2025); FINEVISION HP trifocal IOL (October 2025); Virtuoso® platform (EU MDR CE Mark April 2026, U.S. approval pending)

- 2025 Medical Device Network Excellence Awards: Four awards — Breakthrough Innovation in Ophthalmic Implants (ISOFOCAL), Award-Winning Product Launch (SERENITY IOL Portfolio), R&D Leadership in MIGS (Leos™), and Strategic Capital Investment & Global Expansion ($1B raise)

- Great Place to Work Certification: Certified in 2025 across U.S., France, Netherlands, and Mexico offices

Financial Performance & Funding

Capital Structure

- 2025 Strategic Capital Raise: $1 billion in partnership with TPG; fully refinanced existing debt and added new equity from TPG and additional investors

- Company Type: Privately held (PE-backed)

- Controlling Owner: TPG Capital (since 2016)

- Previous Owner: RoundTable Healthcare Partners (2010–2016)

Company Overview

Corporate Information

Legal Name: BVI Medical, Inc. (fka Beaver-Visitec International Holdings, Inc.)

Founded: 2010 (corporate formation); brand heritage 1932

Headquarters: 303 Wyman Street, Suite 350, Hobbs Brook Office Park, Waltham, MA 02451, USA

Company Type: Privately held corporation

Industry: Ophthalmic Surgical Devices / Medical Devices

Global Presence: 90+ countries

Website: www.bvimedical.com

Leadership (2026)

President & CEO: Jim Hollingshead, PhD (appointed January 19, 2026)

- Brings more than three decades of global leadership across medtech and life Sciences; previously CEO of Insulet Corporation (2022–2025) and President of Sleep and Respiratory Care at ResMed

Former President & CEO: Shervin Korangy (served through January 2026; now advisor to BVI and senior advisor to TPG Capital)

Chief Commercial Officer: Andrew Chang (appointed April 2025)

- Formerly President of Carl Zeiss Meditec USA and Head of Global Sales for Zeiss Ophthalmic Devices

Chief Financial Officer: Todd Patriacca

Chairman: Ron Labrum

Global Communications Lead: David Chavez

Global Manufacturing & Operations

Manufacturing Facilities

- Waltham, MA, USA: Headquarters and manufacturing for surgical instruments and consumables

- Little Silver, NJ, USA: Manufacturing

- Sarasota, FL, USA: Sales and manufacturing; IOL material development and production

- Bidford-on-Avon, UK: Manufacturing for ophthalmic devices

- Halifax (Elland), UK: Distribution center and manufacturing

- Liège, Belgium: IOL manufacturing facility opened July 2023

- Vierpolders, Netherlands: Manufacturing

- Changshu, jiangsu, China: Manufacturing

- Ciudad Juárez, Chihuahua, Mexico: Manufacturing

- Rome, Italy: Sales, manufacturing, and local office

Sales & Local Offices

- USA: Irvine, CA; Waltham, MA; Sarasota, FL; Little Silver, NJ

- Europe: Heidelberg, Germany; Toulouse, France; Dublin, Ireland; Barcelona, Spain; Sant Cugat del Vallès, Spain; Lisbon, Portugal; Bjärred, Sweden; Krakow, Poland

- Asia-Pacific: Tokyo, Japan

- Latin America: São Paulo, Brazil

Subsidiaries & Acquisitions

- MedicalMix: Barcelona, Spain (acquired 2023) — ophthalmic surgery device distributor for Spain and Portugal

- John Bannon: Dublin, Ireland (acquired)

- Arcadophtha: Toulouse, France

- PhysIOL: Premium IOL brand and manufacturing (acquired)

- Benz Research & Development: Acquired to expand IOL material capabilities

Key Competitors

- Alcon: Global market leader in ophthalmic devices

- Johnson & Johnson Vision: Major competitor in IOL and surgical vision care

- Carl Zeiss Meditec: Leading competitor in surgical microscopes and laser platforms

- Bausch + Lomb: Competitor in ophthalmic pharmaceuticals and devices

- Corza Ophthalmology: Direct competitor in ophthalmic surgical devices

Competitive Advantages

- Integrated Portfolio: Full procedural solutions spanning cataract, glaucoma, and vitreoretinal surgery

- IOL Innovation: Proprietary POD platform, GFY material, and ISOFOCAL technology across premium lens portfolio

- Global Scale: 90+ country presence with direct sales and distributor networks; manufacturing across four continents

- Financial Backing: $1B+ capital base from TPG enabling aggressive R&D and expansion

- Manufacturing Flexibility: Multi-continent production footprint including U.S., Europe, china, and Mexico

2026 Strategic Outlook

- U.S. IOL Market Expansion: Scale FINEVISION HP trifocal IOL rollout and introduce SERENITY portfolio to American surgeons

- Glaucoma Commercialization: Launch Leos™ system in the U.S. and expand global ECP market share

- Equipment Segment Growth: Drive Virtuoso® phaco-vitrectomy platform adoption in Europe following EU MDR CE Mark; seek U.S. regulatory clearance

- Retina Portfolio: Expand ISPAN™ ophthalmic gases and vitreoretinal consumables in the Americas

- Global Footprint: Leverage $1B capital raise and BVI Poland Centre of Excellence to expand manufacturing capacity and enter emerging markets

Contact Information

Global Headquarters

Address: 303 Wyman Street, Suite 350, Hobbs Brook Office Park, Waltham, MA 02451, USA

Phone: +1 (866) 906-8080

Website: www.bvimedical.com

Press Contact: David Chavez, Global Communications Lead — +1 (857) 869-8706

Investor / Ownership

Controlling Owner: TPG Capital

Website: www.tpg.com

Keywords: BVI Medical, Beaver-Visitec International, ophthalmic devices, intraocular lens, IOL, cataract surgery, glaucoma, vitreoretinal, retina, Leos, Virtuoso, FINEVISION HP, SERENITY, ISOPURE, IPure, PODEYE, PhysIOL, Beaver, Visitec, Merocel, Weck-Cel, Wet-Field, Vitreq, Malosa, Parasol, ISPAN, TPG, Waltham, Massachusetts, Jim Hollingshead, Shervin Korangy, Andrew Chang, Todd Patriacca, Ron Labrum, FDA 510(k), CE mark, EU MDR, Medical Device Network Excellence Awards, Benz Research, MedicalMix, Poland, Krakow, China, Mexico, Belgium, Netherlands